All In Biotech

Drug Trial Radar · NCT04928846

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 768 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

768

Planned (sponsor's estimate)

Start

Mar 25, 2022

Primary completion

Dec 2028

Study completion Feb 2029

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin or docetaxel at an 1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin or IV infusion of docetaxel. Approximately 768 adult participants with c-Met overexpressing NSCLC will be enrolled in the study in approximately 330 sites worldwide. Participants will receive IV telisotuzumab vedotin every 2 weeks or docetaxel every 3 weeks until meeting study drug discontinuation criteria. At the conclusion of the study, participants who continue to demonstrate clinical benefit may be eligible to receive study treatment via an extension of the study, a rollover study, or through another mechanism. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Non Small Cell Lung Cancer
  • c-MET

Interventions

  • Telisotuzumab VedotinBiological

    Intravenous (IV) Infusion

  • DocetaxelDrug

    IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR)Time frame: Up to approximately 39 months
  2. Overall Survival (OS)Time frame: Up to approximately 39 months

Locations

317 sites in 32 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham - Main /ID# 247074

    Birmingham, Alabama · Completed

  • Ironwood Cancer & Res Ctr /ID# 262446

    Chandler, Arizona · Active not recruiting

  • Mayo Clinic Arizona /ID# 255858

    Phoenix, Arizona · Active not recruiting

  • Onvida Health Yuma Medical Center /ID# 253625

    Yuma, Arizona · Completed

  • City of Hope /ID# 243157

    Duarte, California · Recruiting

  • City Of Hope - Seacliff /ID# 263143

    Huntington Beach, California · Recruiting

  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 263144

    Irvine, California · Recruiting

  • City Of Hope - Antelope Valley /ID# 263138

    Lancaster, California · Recruiting

  • The Oncology Institute Of Hope & Innovation -East Los A /ID# 239774

    Los Angeles, California · Completed

  • Eisenhower Medical Center /ID# 233189

    Rancho Mirage, California · Completed

  • Premiere Oncology Foundation /ID# 253954

    Santa Monica, California · Completed

  • Mayo Clinic Hospital Jacksonville /ID# 254688

    Jacksonville, Florida · Completed

  • Ocala Oncology Florida Cancer Affiliates - Main /ID# 234228

    Ocala, Florida · Completed

  • BRCR Medical Center Inc /ID# 262344

    Tamarac, Florida · Completed

  • Memorial University Medical Center /ID# 264081

    Savannah, Georgia · Completed

  • Kaiser Permanente Moanalua Medical Center /ID# 238363

    Honolulu, Hawaii · Recruiting

  • Edward-Elmhurst Cancer Center /ID# 238552

    Elmhurst, Illinois · Active not recruiting

  • Springfield Clinic - First /ID# 262290

    Springfield, Illinois · Active not recruiting

  • Goshen Center for Cancer Care /ID# 257734

    Goshen, Indiana · Completed

  • Investigative Clinical Research of Indiana - Indianapolis /ID# 260468

    Indianapolis, Indiana · Completed

  • Baptist Health Lexington /ID# 252769

    Lexington, Kentucky · Completed

  • Dana-Farber Cancer Institute /ID# 247132

    Boston, Massachusetts · Completed

  • Trinity Health St. Joseph Mercy Ann Arbor /ID# 232190

    Ypsilanti, Michigan · Completed

  • Mayo Clinic Hospital Rochester /ID# 252052

    Rochester, Minnesota · Active not recruiting

  • Hattiesburg Clinic /ID# 248033

    Hattiesburg, Mississippi · Recruiting

  • St. Luke's Hospital - Chesterfield /ID# 251688

    Chesterfield, Missouri · Completed

  • St. Lukes Hosp. of Kansas City /ID# 259940

    Kansas City, Missouri · Recruiting

  • Alliance for Multispecialty Research (AMR) - Kansas City /ID# 247567

    Kansas City, Missouri · Completed

  • Hulston Cancer Center /ID# 232226

    Springfield, Missouri · Recruiting

  • Saint Louis University Cancer Center /ID# 260722

    St Louis, Missouri · Completed

  • Intermountain Health St Vincent Regional Hospital - Cancer Centers of Montana /ID# 253147

    Billings, Montana · Active not recruiting

  • Nebraska Hematology Oncology /ID# 257710

    Lincoln, Nebraska · Completed

  • Renown Medical Group - Oncology/Hematology /ID# 247942

    Reno, Nevada · Completed

  • Astera Cancer Care /ID# 257753

    East Brunswick, New Jersey · Completed

  • San Juan Oncology Associates /ID# 244387

    Farmington, New Mexico · Completed

  • Maimonides Medical Center /ID# 240783

    Brooklyn, New York · Active not recruiting

  • Northwell Health - Monter Cancer Center /ID# 247081

    Lake Success, New York · Completed

  • AdventHealth Hendersonville /ID# 265349

    Hendersonville, North Carolina · Completed

  • FirstHealth of the Carolinas- Speciality Center /ID# 241279

    Pinehurst, North Carolina · Completed

  • Genesis Cancer Care Center /ID# 239190

    Zanesville, Ohio · Active not recruiting

Showing 40 of 317 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.